DARZALEX® delivers remarkable efficacy in combination with Velcade® (bortezomib) and dexamethasone (Vd) in relapsed/refractory patients with ≥1 prior therapy*
Prof. María-Victoria Mateos discusses 4-year updates on the CASTOR study – DARZALEX®+ Vd in RRMM
CASTOR is a randomised, open-label, active-controlled, multicentre phase 3 study comparing DARZALEX® + Vd (DVd) vs. Vd. N=498
* DVTd vs. VTd alone.
(PDF, 5.8 MB)
CASTOR: Updated analysis presented at the ASH Annual Meeting 2019
DARZALEX® + Vd provided consistently better outcomes across pre-specified patient subgroups:
* DVd vs. Vd alone.
† MRD was assessed via next-generation sequencing on bone marrow aspirate samples that were ficolled and evaluated by the US Food and Drug Administration–approved clonoSEQ® assay V2.0 (Adaptive Biotechnologies, Seattle, WA) at sensitivity thresholds of 10-4 (1 cancer cell per 10,000 nucleated cells), 10-5, and 10-6.
* DRd vs. Vd alone.
1800 mg SC
Cycle 1–3: Weekly
Cycles 4–8: Every 3 weeks
Cycles 9+: Every 4 weeks until disease progression
1.3 mg/m2 SC/IV
Cycles 1–8: Twice weekly on Weeks 1 and 2
20 mg PO†
Cycles 1–8: Days 1, 2, 4, 5, 8, 9, 11 and 12
† On DARZALEX® dosing days, the pre-administration medication replaces the daily dose of dexamethasone.
DVd dosing schedule
(PDF, xx KB)
ASH: American Society of Hematology
DVd: DARZALEX®, Velcade®, dexamethasone
IRR: infusion-related reaction
MRD: minimal residual disease
RRMM: relapsed/refractory multiple myeloma
Vd: Velcade®, dexamethasone